Success Metrics

Clinical Success Rate
63.6%

Based on 7 completed trials

Completion Rate
64%(7/11)
Active Trials
4(24%)
Results Posted
86%(6 trials)
Terminated
4(24%)

Phase Distribution

Ph phase_3
2
12%
Ph phase_1
3
18%
Ph phase_4
4
24%
Ph phase_2
7
41%

Phase Distribution

3

Early Stage

7

Mid Stage

6

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
3(18.8%)
Phase 2Efficacy & side effects
7(43.8%)
Phase 3Large-scale testing
2(12.5%)
Phase 4Post-market surveillance
4(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

63.6%

7 of 11 finished

Non-Completion Rate

36.4%

4 ended early

Currently Active

4

trials recruiting

Total Trials

17

all time

Status Distribution
Active(5)
Completed(7)
Terminated(4)
Other(1)

Detailed Status

Completed7
Recruiting4
Terminated4
unknown1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
4
Success Rate
63.6%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (18.8%)
Phase 27 (43.8%)
Phase 32 (12.5%)
Phase 44 (25.0%)

Trials by Status

unknown16%
completed741%
recruiting424%
enrolling_by_invitation16%
terminated424%

Recent Activity

Clinical Trials (17)

Showing 17 of 17 trials
NCT03785210Phase 2

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Terminated
NCT06817031Phase 2

Maternal Probiotic Intervention to Improve Gut Health - Trial II - Bangladesh

Enrolling By Invitation
NCT07134790Phase 2

Maternal Probiotic Intervention to Improve Gut Health - Trial II - Burkina Faso (MPIGH-II)

Recruiting
NCT07207434Phase 2

Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan

Recruiting
NCT02504554Phase 1

Beneficial Bacteria Treatment for Autism

Completed
NCT05876182Phase 2

Vancomycin in Primary Sclerosing Cholangitis in Italy

Recruiting
NCT04899115Phase 2

VE303 for Treatment of Hepatic Encephalopathy (HE)

Completed
NCT03617445Phase 2

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

Terminated
NCT05320068Phase 3

Oral Vancomycin Vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection

Completed
NCT03466502Phase 4

Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics

Completed
NCT04000555Phase 4

Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

Terminated
NCT05376228

A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD

Unknown
NCT03388268Phase 4

TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment

Completed
NCT03200093Phase 4

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

Terminated
NCT04236778Phase 1

First-in-human Study of VE303 in Healthy Adult Volunteers

Completed
NCT01802073Phase 3

Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

Completed
NCT02137668Phase 1

Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

Recruiting

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17